简体
简体中文
繁體中文

Nuveen AMT-Free Municipal Value Fund NUW

等待开盘 09-04 09:30:00 美东时间

13.73

+0.050

+0.37%

华盛通华盛通
立即下载
  • 最 高13.78
  • 今 开13.75
  • 成交量 7.18万股
  • 最 低 13.66
  • 昨 收 13.68
  • 总市值 2.46亿
  • 52周最高 13.8915
  • 市盈率 9.09
  • 换手率 0.40%
  • 52周最低 12.7975
  • 委 比 33.33%
  • 总股本 1795.13万
  • 历史最高 15.6246
  • 量 比 1.97
  • 振 幅 0.88%
  • 历史最低 9.2376
  • 每 手 1
  • 风险率 0.18%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • 【上证机器人】看好富士康机器人产业链-人形机器人行业观点报告

    (来源:上海证券研究) 1.富士康在机器人领域的相关布局 1)2006年,公司自主研发生产的“富士康深圳一号”机器人亮相深圳第八届高交会;根据《一步步新技...

    08-27 17:14

  • Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus

    Nuwellis, Inc. announced its decision to exit international operations and focus exclusively on the U.S. market due to stronger growth and clinical demand there. The company aims to prioritize investment in high-impact areas like U.S. cardiac surgery, pediatrics, and outpatient care. This strategic move aligns operations with market demand and aims to deliver better patient outcomes and shareholder value. Nuwellis will continue supporting interna...

    08-07 12:15

  • Nuveen AMT-Free Municipal Value Fund declares $0.0485 dividend

    Nuveen AMT-Free Municipal Value Fund (NYSE:NUW) declares $0.0485/share monthly dividend. Forward yield 4.26% Payable Sept. 2; for shareholders of record Aug. 15; ex-div Aug. 15. See NUW Dividend Score...

    08-05 20:50

  • Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code

    Nuwellis, Inc. announced successful treatment of first patients with Aquadex ultrafiltration therapy in a hospital-based outpatient setting, supported by increased reimbursement rates. This milestone improves access to fluid management and offers potential economic and clinical advantages for hospitals and patients.

    08-05 12:15

  • Nuwellis Stockholders Approve All Proposals at Special Meeting

    Nuwellis, Inc. announced that its Special Meeting of Stockholders approved all proposals aimed at enhancing financial flexibility and supporting strategic growth. These include the issuance of shares under warrants, increasing authorized common stock from 100 million to 200 million, and authorizing a reverse stock split ratio between 1-for-5 and 1-for-70. CEO John Erb thanked stockholders, noting these approvals strengthen Nuwellis's capital posi...

    08-04 21:24

  • Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

    <p>Nuwellis, Inc.的总裁兼首席执行官John Erb参加了Virtual Investor举办的夏季专题虚拟会议,并分享了他对公司的奉献以及他对公司开发项目热衷的原因。该会议的视频重播现已在www.virtualinvestorco.com及Nuwellis官网的投资者页面上提供。</p>

    07-23 12:45

  • Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025

    Nuwellis, Inc. will release its second quarter 2025 financial results on August 12, 2025, and host a conference call and webcast at 9:00 AM ET to discuss the results. Interested parties may access the live webcast via the Investors page of the Nuwellis website or by dialing the provided conference call numbers using the ID NUWEQ2. The company, focused on treating fluid overload, commercializes the Aquadex SmartFlow® system for ultrafiltration the...

    07-22 12:15

  • 这个周末,基金高管“变更潮”来袭

    作者 | 佳启 编辑 | 袁畅 这个周末,公募基金业同时发布多份重磅的高管变更公告,这使得7月第三个周末成为公募高管的“变动周”。 7月19日公告变更的高...

    07-19 16:14

  • Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

    Nuwellis, Inc. has announced the termination of its REVERSE-HF clinical trial on July 17, 2025, redirecting resources toward outpatient markets for greater impact. The decision prioritizes scalable growth areas like outpatient heart failure, pediatric, and critical care. Nuwellis expects to save $4.0M over 2.5 years and will continue supporting current strong growth in pediatric and critical care. The trial enrolled 167 patients since 2022, and t...

    07-17 11:35

  • Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation

    Nuwellis, Inc. announced the issuance of U.S. Patent No. 12,357,734 by the U.S. Patent and Trademark Office on July 15, 2025. The patent covers improvements in fluid balance calculations for extracorporeal blood filtering systems by accounting for varying fluid densities, reducing errors in continuous renal replacement therapy. This addition strengthens Nuwellis' intellectual property portfolio and demonstrates their commitment to innovation in f...

    07-15 20:05